Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study
IntroductionLong COVID is a public health issue with complex pathophysiology, potentially involving immunoinflammatory and prothrombotic mechanisms. Antiphospholipid antibodies (aPL) have been observed in acute COVID-19 and speculated to contribute to long COVID development. Our goal was to determin...
Saved in:
| Main Authors: | Robin Arcani, Alexandre Brodovitch, Xavier Heim, Jean-Louis Mège, Nathalie Bardin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1634663/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
by: Jin Zhang, et al.
Published: (2021-01-01) -
Infection-Triggered Antiphospholipid Syndrome: A Critical Overview
by: Smiyan S, et al.
Published: (2025-08-01) -
Antiphospholipid Antibodies and COVID‐19: A Systematic Review of Clinical Implications
by: Tahereh Sabaghian, et al.
Published: (2025-02-01) -
Neonatal intracardiac thrombosis secondary to transplacental transfer of maternal antiphospholipid antibodies-a case report and review of the literature
by: Katherine Girgulis, et al.
Published: (2025-05-01) -
Improving diagnosis in patients with obstetric antiphospholipid syndrome through the evaluation of non‐criteria antibodies
by: Daniel Álvarez, et al.
Published: (2024-01-01)